drugset / Trial / NCT03709121

A Methodology Development Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber

NCT03709121

Phase 1/2 Completed 70 enrolled Aldeyra Therapeutics, Inc.
RandomizedCrossoverQuadruple-blindTreatment

Summary

An Exploratory Clinical Trial Evaluating Reproxalap Ophthalmic Solutions (0.25% and 0.5%) in Subjects with Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber (EEC)

Timeline

Start
2018-10-02
Primary completion
2019-03-20
Completion
2019-03-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Reproxalap Other / unclassified 0.25 %
Subject Reproxalap Other / unclassified 0.5 %

Indications